Robert Hugin, Celgene

Chairman and CEO, Celgene
Total 2014 Compensation: $24.24 million

Celgene's Bob Hugin might have been beat out by the CEOs of fellow biologic drugmakers Regeneron ($REGN) and Vertex ($VRTX) on this list, but he's still the highest-paid executive in Big Biotech--and he beats out quite a few in Big Pharma as well.

That's partly because Celgene ($CELG) is one of the fastest-growing drugmakers on the scene. Of the pharma companies in the Fortune 500, Celgene came in second for sales growth over the past 5 years, partly because its blood cancer treatment Revlimid just can't be stopped (at least not till biosimilars appear on the scene in the coming years).

With a 5-year annual growth rate of 23.3% and $7.7 billion in 2014 revenue, the company is on its way to Hugin's ambitious goal of $12 billion in sales by 2017. Revlimid accounted for almost $5 billion of that 2014 revenue, and it has since won a new indication in newly diagnosed multiple myeloma patients. Even with the spectre of biosimilars, EvaluatePharma predicts $8 billion-plus in Revlimid sales by 2020.

Plus, Celgene can boast some industry-leading margins. According to Investor's Business Daily, Celgene delivered a 47% margin last year, again thanks to Revlimid.

But the company won't be relying on Revlimid forever. It has a follow-up multiple myeloma drug, Pomalyst, that it's currently selling as a third-line treatment, but hoping to move to the first-line setting down the road. And it's working to move into anti-inflammatories with Otezla, which has new indications in psoriasis and psoriatic arthritis--and it's a pill, not an injection like its big-time rivals, such as AbbVie's ($ABBV) Humira and Amgen's ($AMGN) Enbrel.

Hugin collected on those accomplishments in his 2014 pay package, with more than $9 million in cash incentive pay and options awards alike. His stock awards amounted to $3.9 million. And all that came on top of a base salary of $1.38 million. Other compensation of $231,000 completed the package.

For more:
Special Reports: 15 Highest-Paid Biopharma CEOs of 2013 - Robert Hugin - Celgene | The top 10 most expensive drugs of 2013 - Pomalyst - Revlimid
Which Big Biotechs join Gilead in Fortune's fastest-growing pharma ranks?
Celgene's R&D speed dating is starting to pay off, CEO says

Move over, Big Pharma: Smaller biopharma's execs are bringing home more bacon
Who's king of the orphan drug hill? BMS, Merck, Celgene and Roche, to name a few
Celgene's Otezla nabs psoriasis approval, launching next-gen showdown

Robert Hugin, Celgene
Read more on

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.